Latham & Watkins represented the underwriters in the IPO while Goodwin advised PepGen. PepGen, Inc., a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with...
You must be a Standard 1 Year member to access this content.
Goodwin advised Gandeeva on the deal. Gandeeva announced its Series A funding led by Lux Capital and Leaps by Bayer, with participation from Obvious Ventures, Amgen Ventures,...
You must be a Standard 1 Year member to access this content.
Wilmer Cutler Pickering Hale and Dorr advised the underwriters on the deal while Goodwin Procter represented Amylyx Pharmaceuticals. Amylyx Pharmaceuticals, Inc. (“Amylyx”), a clinical-stage pharmaceutical company...
You must be a Standard 1 Year member to access this content.
Sidley Austin advised Sixth Street and Goldman Sachs on the deal while Goodwin Procter LLP represented Datavant. Ropes & Gray represented New Mountain Capital and its...
You must be a Standard 1 Year member to access this content.
Goodwin Procter LLP advised Chiasma, Inc. on the deal. Chiasma, Inc. (Nasdaq: CHMA) announced its definitive agreement to be acquired by Amryt Pharma plc (Nasdaq: AMYT, AIM:...
You must be a Standard 1 Year member to access this content.
Goodwin Procter LLP advised Charlesbank Capital Partners on the deal. Charlesbank Capital Partners, a middle-market private investment firm, announced that an affiliated fund has made a significant...
You must be a Standard 1 Year member to access this content.
Goodwin Procter LLP advised Markforged on the deal, while Cadwalader advised One.Markforged announced its definitive agreement to merge with One (NYSE: AONE), a special purpose acquisition company...
You must be a Standard 1 Year member to access this content.
